An interventional study of Galvanic Vestibular Stimulation (GVS) and Flight simulations in virtual reality (VR) in Motion Sickness, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment
The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.
The Three-Axis Wearable Adaptive Vestibular Stimulator (3WAVeS) technology that combines galvanic vestibular stimulation (GVS) and Virtual Reality (VR) will not only increase VR-based simulation realism and presence, but will also mitigate the motion sickness often associated with VR simulation by re-coupling the vestibular and ocular inputs to the VR user. Additionally, due to GVS technology's ability to accurately provide continuous inputs to the vestibular system, 3WAVeS can intentionally simulate high-fidelity effects of spatial disorientation for training purposes.
50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.
This study's planned enrollment of 40 is below the median of 59 across 44 interventional studies indexed under Motion Sickness.
Browse Motion Sickness studies →Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- History of vestibular disease, migraine, or significant balance disorder; history of severe motion sensitivity, women who are pregnant.
Subjects will receive positive galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
Device: Galvanic Vestibular Stimulation (GVS) · Other: Flight simulations in virtual reality (VR)
Subjects will receive negative galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
Device: Galvanic Vestibular Stimulation (GVS) · Other: Flight simulations in virtual reality (VR)
Subjects will not receive any galvanic vestibular stimulation (GVS) during a flight simulation in virtual reality (VR).
Other: Flight simulations in virtual reality (VR)
Subjects will receive positive galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
Device: Galvanic Vestibular Stimulation (GVS) · Other: 3-DOF Bertec Portable Essential's dual-balance force plate system
Subjects will receive negative galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
Device: Galvanic Vestibular Stimulation (GVS) · Other: 3-DOF Bertec Portable Essential's dual-balance force plate system
Subjects will not receive any galvanic vestibular stimulation (GVS) while utilizing the 3-DOF Bertec Portable Essential's dual-balance force plate system.
Other: 3-DOF Bertec Portable Essential's dual-balance force plate system
Four electrodes, forehead, behind both ears, and back of your neck, provide bidirectional electrical stimulation and receive information about the amplitude delivered accounting for skin impedance
Highly immersive, 3D virtual flight simulation environment
Firm surface/plate to stand on while being presented disorienting visual patters of moving vertical and/or horizontal bars of alternating black and white.
Pensacola Diagnostic Index-based motion sickness questionnaire
This index allowed a comparison of motion sickness severity across subjects that may each present with a different constellation of symptoms like nausea, skin color, sweating, salivation, drowsiness, headache, and dizziness. The approach is to have the subject and/or observer grade the subjective intensity of different modalities of symptoms and signs (described below) as slight, moderate or severe. Overall motion sickness severity is then derived from a sum of scores resulting in a weighted "malaise index".
Time frame: Immediately after each flight stimulation session, approximately 1 hour
COG Sway velocity
The sway angle of the center of gravity (COG) is the measure the amount of sway in any direction. The COG sway velocity is the ratio of the distance traveled by the COG (degrees) to the time (sec) of the trial.
Time frame: Immediately after balance testing in each session, approximately 1 hour
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Dec 2025, 24 months.
Of 15 interventional studies with no phase under Motion Sickness, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 29. This study's 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.